Skip to contentK
Korro Bio, Inc.
K
KRROKorro Bio, Inc. Q3 2025 · 10-Q
Revenue$1.09M$1.09M— vs Q3 2024 Net Income-$18.06M-$18.06MN/M vs Q3 2024 EPS Diluted-$1.92-$1.92N/M vs Q3 2024 Operating Income-$19,237,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Korro Bio, Inc. · CIK 1703647 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$17,354,000N/M Margins · derivedOperating margin-1764.9%
Net margin-1657.0%
ended Sep 30, 2025 · filed Nov 12, 2025 · 43 d after period end